Affiliation:
1. 1Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
2. 2Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Abstract
The acute metabolic actions of purified human growth hormone (GH) were first documented in adult hypopituitary patients more than 50 years ago, and placebo-controlled long-term GH trials in GH-deficient adults (GHDA) surfaced in 1989 with the availability of biosynthetic human GH. Untreated GHDA is associated with excess morbidity and mortality from cardiovascular disease and the phenotype includes fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia and elevated levels of circulating cardiovascular biomarkers. Several of these features reverse and normalize with GH replacement. It remains controversial whether quality of life, assessed by questionnaires, improves. The known side effects are fluid retention and insulin resistance, which are reversible and dose dependent. The dose requirement declines markedly with age and is higher in women. Continuation of GH replacement into adulthood in patients with childhood-onset disease is indicated, if the diagnosis is reconfirmed. GH treatment of frail elderly subjects without documented pituitary disease remains unwarranted. Observational data show that mortality in GH-replaced patients is reduced compared to untreated patients. Even though this reduced mortality could be due to selection bias, GH replacement in GHDA has proven beneficial and safe.
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism
Reference200 articles.
1. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH;Journal of Clinical Endocrinology and Metabolism,1993
2. Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset;European Journal of Endocrinology,1994
3. Cancer Incidence in Patients with Acromegaly: a cohort study and meta-analysis of the literature;Journal of Clinical Endocrinology and Metabolism,2018
4. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality;Journal of Clinical Endocrinology and Metabolism,2011
5. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children.;Journal of Clinical Endocrinology and Metabolism,1999
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献